An observational study in Hypercortisolism and Arterial Hypertension, sponsored by Istituto Auxologico Italiano. Status unknown at 1 site in Italy. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-13.
Sponsored by Istituto Auxologico Italiano · Observational
The goal of this observational study is to evaluate, between patients with arterial hypertension and non hypertensive control group,
130 studies on the registry are indexed under Cushing Syndrome; 40 are open to participants now.
This study's planned enrollment of 290 is above the median of 121 across 67 observational studies indexed under Cushing Syndrome.
Browse Cushing Syndrome studies →Istituto Auxologico Italiano is the lead sponsor of 202 studies on the registry; 78 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hypertension group: patients with hypertension referred to the cardiology clinics of Istituto Auxologico Italiano, Milan No hypertension group: patients without hypertension referred to endocrinology clinics of Istituto Auxologico Italiano for other diseases (e.g. euthyroid nodular goiter or chronic lymphocytic euthyroid thyroiditis)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those patients suffering from arterial hypertension
Diagnostic Test: Dexamethasone suppression test
Those patients without arterial hypertension
Diagnostic Test: Dexamethasone suppression test
Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
Prevalence of hidden hypercortisolism (HidHyCo)
The presence of HidHyCo will be evaluated through the determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mgDST). In case of 1mgDST \>1.8 µg/dL the patient will repeat the test and, if the result is confirmed, the patients is considered to have HidHyCo.
Time frame: At baseline
Evaluation of organ damage
Organ damage will be assessed by performing echocardiography, carotid echo-doppler (arterial stiffness) and microalbuminuria evaluation, which assess hypertensive heart disease, macro-angiopathy and hypertensive nephropathy, respectively
Time frame: At baseline
Evaluation of oxidative stress level
The determination of the degree of oxidative stress will be carried out in all patients by evaluating the enzymatic activity of dipeptidyl peptidase 3 (DPP3) in the serum
Time frame: At baseline
Evaluation of cortisol secretion degree
The cortisol secretion will be evaluated by measuring morning plasma ACTH and serum cortisol, 24-hour urinary free cortisol, serum cortisol at 09:00 after the administration of 1 mg dexamethasone at 11 PM on the previous day
Time frame: At baseline
Evaluation of glucocorticoid sensitivity
In all subjects, genotyping of the N363S, BclI, ER22/23EK polymorphisms of the GR gene and of the polymorphisms will be performed
Time frame: At baseline
Evaluation of glucocorticoid peripheral activity
Urinary free cortisol and urinary free cortisone will be measured in all subjects; their ratio will be used as measure of glucocorticoid peripheral activity
Time frame: At baseline
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →